Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | POLG | P54098 | 1/20 | 0.67 |
| ▸ | FAP | Q12884 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391569 | 0.85 | SLC22A6 (0.84) | SLC22A6ABCB11POLA1POLGFAP | |
| Adefovir SCHEMBL28809752 | 0.83 | FGFR1 (0.78) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL20718818 | 0.82 | SLC22A6 (0.77) | SLC22A6ABCB11POLA1POLGFAP | |
| Adefovir SCHEMBL17599216 | 0.82 | FGFR1 (0.83) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL12875233 | 0.82 | FGFR1 (0.78) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL3720707 | 0.82 | SLC22A6 (0.76) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL2788054 | 0.81 | SLC22A6 (0.57) | SLC22A6ABCB11POLA1POLGFAP | |
| SCHEMBL24721836 | 0.81 | FGFR1 (0.77) | SLC22A6ABCB11POLA1POLGFAP | |
| Adefovir Dipivoxil SCHEMBL29729 | 0.80 | FAP (1.00) | SLC22A6ABCB11POLA1POLGFAP | |
| Adefovir Dipivoxil SCHEMBL29372789 | 0.80 | FAP (1.00) | SLC22A6ABCB11POLA1POLGFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140114-B1 | PHARMACEUTICAL FORMULATIONS | GILEAD SCIENCES INC (US) | 2005-06-29 | — | — | EP | claimed |
| US-9169257-B2 | Crystal forms of adefovir dipivoxil and processes for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-10-27 | — | — | US | disclosed |
| US-9169257-B2 | Crystal forms of adefovir dipivoxil and processes for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-10-27 | — | — | US | disclosed |
| CN-102365283-B | Novel crystal forms of adefovir dipivoxil and processes for preparing same | DAE WOONG PHARMA | 2014-04-09 | — | — | CN | disclosed |
| EP-2411392-B1 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2014-02-26 | — | — | EP | disclosed |
| US-20120101273-A1 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | Novel Crystal Forms of Adefovir Dipivoxil and Processes for Preparing the Same (KR) | 2012-04-26 | — | — | US | disclosed |
| US-20120101273-A1 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | Novel Crystal Forms of Adefovir Dipivoxil and Processes for Preparing the Same (KR) | 2012-04-26 | — | — | US | disclosed |
| CN-102365283-A | Novel crystal forms of adefovir dipivoxil and processes for preparing the same | DAE WOONG PHARMA | 2012-02-29 | — | — | CN | disclosed |
| EP-2411392-A2 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411392-A2 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110622-A3 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010110622-A9 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010110622-A9 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010110622-A2 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110622-A2 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101273-A1 | NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME | ADA, ADAR, DCTD | SLC22A6 3193/4885ABCB11 2317/4885POLA1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.